The U.S. Food and Drug Administration (FDA) has cleared Cytrellis Biosystems’ ellacor micro-coring technology device to treat sagging skin on body areas.
This new indication expands ellacor’s use beyond the face. ellacor removes micro-cores of skin without surgery or the use of heat. Removing a fraction of the skin at a time stimulates the body’s natural collagen and elastin production.
“ellacor allows physicians to treat skin without the use of energy, scarring, or surgery,” says William Austen, MD, Cytrellis co-founder and Chief of Burn Surgery, Oral & Maxillofacial Surgery at Massachusetts General Brigham in Boston, MA, in a news release. “With a solid foundation of robust clinical data, this approach enables precise and controlled skin removal across multiple areas of the body.”
Rox Anderson, MD, Cytrellis co-founder and Director of the Wellman Center for Photomedicine and Lancer Endowed Chair in Dermatology at Massachusetts General Brigham, adds, “The ability to precisely remove micro-portions of skin anywhere on the body opens a new category of skin restoration. We’re proud to see years of research and collaboration with clinicians now translating into broader patient benefit.”
